摘要
目的观察老年颈动脉粥样硬化(CAS)患者行血脂康胶囊治疗前后的颈动脉内膜中层厚度(CIMT)、血脂、白细胞分化抗原40及其配体(CD40/CD40L)和基质金属蛋白酶9(MMP-9)变化,探讨血脂康胶囊对患者上述指标的影响。方法选择CAS患者60例(CAS组),其中合并脑梗死(CI)34例;健康体检者20例(对照组)。CAS组用血脂康胶囊治疗24周,治疗前后行颈CIMT检测,采用ELISA法检测血清CD40/CD40L和MMP-9,并行血脂检测。对照组在查体时检测上述指标。结果与对照组比较,CAS组CIMT及血清CD40、CD40L、MMP-9明显升高(P<0.05或<0.01);CAS合并CI患者的CIMT及血清CD40、CD40L、MMP-9较无CI患者明显升高,CAS组治疗前后的CIMT及血清CD40、CD40L、MMP-9比较有统计学差异(P均<0.05)。结论血脂康胶囊可通过调节血脂水平,降低CAS患者的CIMT及血清CD40、CD40L、MMP-9,从而延缓CAS进展,减少CI发生率。
Objective To observe the changes of carotid intima-media thickness （ CIMT）, blood lipid, CD40/CD40L and matrix metalloproteinase 9 （MMP-9） in elderly patients with carotid atherosclerosis （CAS） before and after treatment of Xuezhikang capsule, and to investigate the effects of Xuezhikang capsule on these indictors. Methods Sixty patients with CAS （CAS group） which complicated with cerebral infarction （CI） in 34 cases, and 20 cases of healthy people （control group） were selected. The patients with CAS were treated with Xuezhikang capsule for 24 weeks. The CIMT before and after treatment in the CAS group was measured by ultrasound, meanwhile, the levels of CD40/CD40L and MMP-9 were de- tected by ELISA, and the lipid testing was conducted. These indexes were detected in the control group during the physical examination. Results Compared with the control group, the CIMT, serum CD40, CD40L and MMP-9 in the CAS group were significantly increased （P 〈 0.05 or 〈 0.01 ）. The CIMT, serum CD40, CD40L and MMP-9 in patients with CAS complicated with CI were significantly higher than those without CI. The CIMT, CD40, CD40L and MMP-9 were significandy different in CAS patients before and after treatment （ all P 〈 0.05）. Conclusion Xuezhikang capsule may slow down the progression of CAS and reduce the incidence of CI by adjusting blood lipid levels, and lowering the CIMT, serum CD40, CD40 and MMP-9.
出处
《山东医药》
CAS
2013年第33期9-11,共3页
Shandong Medical Journal
基金
湖北省科技厅自然科学基金资助项目(2011CDB369)
